Related Experiment Video
Updated: Jan 12, 2026

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
Targeting Amyloid Toxicity: Novel Cholinesterase Inhibitors Protect Hippocampal Cells from Amyloid Peptide-Derived
Sona Buloyan1,2, Anahit Poghosyan1, Hayk Harutyunyan3,4
1Scientific Technological Center of Organic and Pharmaceutical Chemistry, A. Mnjoyan Institute of Fine Organic Chemistry of National Academy of Sciences of the Republic of Armenia, 26 Azatutian Ave, Yerevan, 0014, Armenia.
Abstract:
Alzheimer's disease (AD) is one of the most common neurodegenerative disorders. The accumulation of amyloid-beta (Aβ) deposits in the brain is considered a major cause of the disease. Acetylcholinesterase (AChE) plays a unique role in AD pathogenesis: (1) its overactivity reduces acetylcholine (ACh) levels, leading to degeneration of the cholinergic system, and (2) it is consistently colocalized with amyloid deposits, where it may promote amyloid fibril formation. AChE binds to Aβ, thereby facilitating both fibril assembly and the resulting neurotoxicity. It is widely accepted that compounds inhibiting AChE activity or binding to the enzyme may serve as effective therapeutic agents for AD. A new group of AChE inhibitors-N-substituted amino acid dialkyl-aminoalkylamides-has been developed. In this study, we evaluated the neuroprotective properties of three novel cholinesterase (ChE) inhibitors: TVA (N-benzoyl-DL-valine-dimethylaminoethylamine iodometilate), TVS (1-diethylaminoethyl-2-phenyl-4-benzylidene-5-imidazolone), and TVV (2-phenyl-4-(p-toluenesulfonyloxybenzylidene)-5-imidazolone) using a primary rat hippocampal neuron culture model treated with Aβ25-35. We investigated the concentration-dependent effects of these compounds. The resulting dose-response curves had two distinct phases: lower concentrations (< 10⁻² mg/ml) exhibited anti-amyloid or therapeutic activity, while higher concentrations (> 10⁻² mg/ml) were toxic to hippocampal neurons. The beneficial effects were confirmed by multiple assays, including LDH activity, lactate content, cresyl violet staining, Calcein AM/PI double staining, and NF/GFAP immunostaining. TVA and TVV at 10⁻² mg/ml effectively attenuated Aβ25-35-induced (20 µg/ml) neuronal damage. Our findings demonstrate that members of the newly synthesized N-substituted amino acid dialkyl-aminoalkylamide family-particularly TVA and TVV-possess strong protective activity against Aβ25-35-induced toxicity in primary rat hippocampal neurons. Interaction with AChE, leading to either enzyme inhibition or conformational changes, is proposed as the primary mechanism underlying their neuroprotective effects.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...

